ArticleJACC. Heart failure2015
Prognostic Significance and Determinants of the 6-Min Walk Test in Patients With Heart Failure and Preserved Ejection Fraction.
Article in JACC. Heart failure, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06675448 (In Search of Best Practices for Patients With Heart Failure and Secondary Mitral Regurgitation), which is not on this map. Cited by 30 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
In Search of Best Practices for Patients With Heart Failure and Secondary Mitral Regurgitation: An Evaluation of the Inova Heart Failure Treatment Algorithm
Who cites it
30 citing papers in PubMed, 2 syntheses or guidelines pooled it, 73 citations in OpenAlex.
- Comparative effects of glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors on heart failure with preserved ejection fraction in diabetic patients: a meta-analysis.Cardiovascular diabetology · 2024Pooled it
- Physical functional performance and prognosis in patients with heart failure: a systematic review and meta-analysis.BMC cardiovascular disorders · 2020Pooled it
- Semaglutide and Exercise Function in Obesity-Related HFpEF: Insights From the STEP-HFpEF Program.JACC. Heart failure · 2025Trial
- Effects of Web-Based Symptom Monitoring Program on Symptom Interference, Physical Activity, and Emergency Department Readmissions in Patients With Pre-Capillary Pulmonary Hypertension: Randomized Controlled Trial.Journal of medical Internet research · 2025Trial
- Statin therapy improves locomotor muscle microvascular reactivity in patients with heart failure with preserved ejection fraction.American journal of physiology. Heart and circulatory physiology · 2024Trial
- Response to Endurance Exercise Training in Older Adults with Heart Failure with Preserved or Reduced Ejection Fraction.Journal of the American Geriatrics Society · 2017Trial
- Left atrial stiffness, exercise intolerance and injury biomarkers predict adverse outcomes in patients with heart failure with preserved ejection fraction.NPJ cardiovascular health · 2026Article
- Long-term outcomes following sacubitril/valsartan therapy for chronic HFrEF: an Italian real-world multicentre study.ESC heart failure · 2026Article
- Geriatric Vulnerabilities Among Adults With Heart Failure With Preserved Ejection Fraction: A Cross-Continent Evaluation.JACC. Advances · 2025Article
- Correlation of Sit-to-Stand Test and 6-Minute Walk Test to Illustrate Cardiorespiratory Fitness in Systolic Heart Failure Patients.Annals of rehabilitation medicine · 2025Article
- Skeletal Muscle SIRT3 Deficiency Contributes to Pulmonary Vascular Remodeling in Pulmonary Hypertension Due to Heart Failure With Preserved Ejection Fraction.Circulation · 2024Article
- Haemodynamic phenotypes of pulmonary hypertension associated with left heart disease: a moving target.The European respiratory journal · 2024Article
- The Long-Term Benefit of Sacubitril/Valsartan in Patients with HFrEF: A 5-Year Follow-Up Study in a Real World Population.Journal of clinical medicine · 2023Article
- Cardiovascular responses to static handgrip exercise and postexercise ischemia in heart failure with preserved ejection fraction.Journal of applied physiology (Bethesda, Md. : 1985) · 2023Article
- Exercise testing in heart failure with preserved ejection fraction: an appraisal through diagnosis, pathophysiology and therapy - A clinical consensus statement of the Heart Failure Association and European Association of Preventive Cardiology of the European Society of Cardiology.European journal of heart failure · 2022Article
- Prognostic impact of left atrial function in heart failure with preserved ejection fraction in sinus rhythm vs. persistent atrial fibrillation.ESC heart failure · 2022Article
- Heart failure with preserved ejection fraction after left-sided valve surgery: prevalent and relevant.European journal of heart failure · 2021Article
- Associations of Cardiac Mechanics With Exercise Capacity: The Multi-Ethnic Study of Atherosclerosis.Journal of the American College of Cardiology · 2021Article
- Association between ventilatory efficiency, oxygen uptake, and Glittre-ADL test results in patients with chronic heart failure: a preliminary study.BMC research notes · 2021Article
- Persistent atrial fibrillation in heart failure with preserved ejection fraction: Prognostic relevance and association with clinical, imaging and invasive haemodynamic parameters.European journal of clinical investigation · 2020Observational
Corrections and comments
- Commented on by
Authors and funding
13 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThis study sought to define the prognostic significance and clinical determinants of the 6-min walk distance (6-MWD) in affected patients.
backgroundSymptoms of exertional fatigue and dyspnea, as well as a reduced exercise tolerance, are cardinal features of pulmonary hypertension associated with heart failure and preserved ejection fraction (PH-HFpEF). Mechanisms limiting exercise capacity in this specific entity remain incompletely understood.
methodsConsecutive patients with PH-HFpEF, as confirmed by right heart catheter, were enrolled in our prospective registry. Hospitalization for HF and/or death for cardiac reasons were defined as primary outcome. Multiple regression models were constructed to establish determinants of the 6-MWD. For quantification of left ventricular (LV) extracellular matrix (ECM), myocardial biopsies were taken from 18 patients.
resultsBetween December 2010 and July 2013, 142 PH-HFpEF patients were included in the study. After a mean follow-up of 14.0 ± 10.0 months, 43 patients (30.3%) reached the combined endpoint. The 6-MWD was found to be an independent predictor of outcome and was influenced by a variety of clinical, echocardiographic, hemodynamic, laboratory, and pulmonary parameters. There was a significant inverse correlation between the 6-MWD and the extent of ECM in the LV myocardium.
conclusionsImpaired exercise capacity in PH-HFpEF patients is explained by cardiac and noncardiac factors. The 6-MWD predicts outcome and may be a useful endpoint in clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.